With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Phase 2 trials often rely on surrogates for overall survival, most commonly overall response rate (ORR) in those evaluating checkpoint inhibitors. So it’s a shame ORR is actually pretty poorly correlated with OS and that progression-free survival at 6 months is much better.